These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19720497)

  • 21. Tardive dyskinesia in older out-patients: a follow-up study.
    Labbate LA; Lande RG; Jones F; Oleshansky MA
    Acta Psychiatr Scand; 1997 Sep; 96(3):195-8. PubMed ID: 9296550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurobehavioral assessment of children and adolescents attending a developmental disabilities clinic.
    Brasić JR; Barnett JY; Kowalik S; Tsaltas MO; Ahmad R
    Psychol Rep; 2004 Dec; 95(3 Pt 2):1079-86. PubMed ID: 15762388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Matson JL; Fodstad JC; Rivet TT
    J Intellect Dev Disabil; 2008 Dec; 33(4):337-44. PubMed ID: 19039694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 10-year follow-up study of tardive dyskinesia.
    Yassa R; Nair NP
    Acta Psychiatr Scand; 1992 Oct; 86(4):262-6. PubMed ID: 1360742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.
    Bradley EA; Lunsky Y; Berg JM; Brooks-Hill RW; O'Leary DA; Harman KE; Korossy M
    Can J Psychiatry; 2002 Oct; 47(8):785; author reply 785-6. PubMed ID: 12420658
    [No Abstract]   [Full Text] [Related]  

  • 27. The treatment of tardive dyskinesia.
    Raja M
    Schweiz Arch Neurol Psychiatr (1985); 1996; 147(1):13-8. PubMed ID: 8685689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tardive dyskinesia and psychotropic drug history.
    Simpson GM; Varga E; Lee JH; Zoubok B
    Psychopharmacology (Berl); 1978 Jul; 58(2):117-24. PubMed ID: 28544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects.
    Rao JM; Cowie VA; Mathew B
    Acta Psychiatr Scand; 1987 Nov; 76(5):507-13. PubMed ID: 2893512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for tardive dyskinesia in a large population of youths and adults.
    Wszola BA; Newell KM; Sprague RL
    Exp Clin Psychopharmacol; 2001 Aug; 9(3):285-96. PubMed ID: 11534539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a screening tool to assess risk of tardive dyskinesia.
    Taylor J
    Br J Nurs; 2002 Mar 28-Apr 10; 11(6):374-8. PubMed ID: 11979217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermittent neuroleptic therapy and tardive dyskinesia: a literature review.
    Goldman MB; Luchins DJ
    Hosp Community Psychiatry; 1984 Dec; 35(12):1215-9. PubMed ID: 6150891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [D3 agonism: an augmentative treatment in tardive dyskinesia? A case report].
    Rehor G; Eiler M; Conca A
    Psychiatr Prax; 2008 Nov; 35(8):404-5. PubMed ID: 18504692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.
    Mentzel CL; Bakker PR; van Os J; Drukker M; Matroos GE; Hoek HW; Tijssen MA; van Harten PN
    J Clin Psychiatry; 2017 Mar; 78(3):e279-e285. PubMed ID: 28199071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis.
    Giménez-Roldán S; Mateo D; Bartolomé P
    Acta Psychiatr Scand; 1985 May; 71(5):488-94. PubMed ID: 2861717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tardive dyskinesia: managing a common neuroleptic side effect.
    Jeste DV; Krull AJ; Kilbourn K
    Geriatrics; 1990 Dec; 45(12):49-54. PubMed ID: 1979304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tardive dyskinesia with schizophrenic relapse.
    Jawed SH; Singh I
    J Ment Defic Res; 1989 Aug; 33 ( Pt 4)():331-4. PubMed ID: 2570160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing neuroleptic-induced tardive dyskinesia in adults and children.
    Lam RW; Jeste SD; Jeste DV
    Encephale; 1988 Sep; 14 Spec No():251-5. PubMed ID: 2905652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia.
    Elliott KJ; Lewis S; el-Mallakh RS; Looney SW; Caudill R; Bacani-Oropilla T
    Ann Clin Psychiatry; 1994 Sep; 6(3):197-203. PubMed ID: 7881501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal.
    Kirch D; Hattox S; Bell J; Murphy R; Freedman R
    Psychiatry Res; 1983 Jul; 9(3):217-23. PubMed ID: 6137850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.